Iovance Biotherapeutics (IOVA) Stock Statistics & Valuation Metrics

Iovance Biotherapeutics has a market cap or net worth of $915.49M. The enterprise value is $327.34M.

Iovance Biotherapeutics has 361,853,880 shares outstanding. The number of shares has decreased by -2.65% in one year.

Iovance Biotherapeutics’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -48.20%.

The current PE Ratio of Iovance Biotherapeutics is ―. Iovance Biotherapeutics’s PEG ratio is ―.

In the last 12 months, Iovance Biotherapeutics had revenue of 164.07M and earned -372.18M in profits. Earnings per share was -1.28.

In the last 12 months, operating cash flow was -303.41M and capital expenditures -20.13M, giving a free cash flow of -323.54M billion.

Iovance Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Iovance Biotherapeutics upcoming earnings date is Nov 6, 2025, TBA (Confirmed).

Iovance Biotherapeutics as a current ratio of 3.74, with Debt / Equity ratio of 7.61%

In the past 12 months, Iovance Biotherapeutics has paid -2.83M in taxes.

Iovance Biotherapeutics EV to EBITDA ratio is -5.94, with an EV/FCF ratio of -5.73.

Iovance Biotherapeutics has $301.18M in cash and marketable securities with $53.17M in debt, giving a net cash position of -$248.02M billion.

Gross margin is 20.60%, with operating margin of -240.92%, and net profit margin of -226.84%.

The average price target for Iovance Biotherapeutics is $10.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy